Renal Cell Carcinoma

For years, adjuvant therapy for renal cell carcinoma was ‘under future direction’ in any research discussion.

Post-nephrectomy recurrence appeared associated with shorter survival among patients with intermediate-high or high-risk renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Most patients with renal cell carcinoma who received commercially available COVID-19 vaccines mounted sufficient antibody response, according to study results presented at International Kidney Cancer Symposium.

Practice type may significantly influence providers’ choice of first-line therapy for metastatic renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

The combination of cabozantinib and nivolumab showed promising efficacy for certain patients with metastatic non-clear cell renal cell carcinoma, according to phase 2 study results presented at International Kidney Cancer Symposium.

Radiation prior to combination immunotherapy did not influence clinical outcomes among patients with metastatic renal cell carcinoma and bone metastases, according to study results presented at International Kidney Cancer Symposium.

COVID-19 vaccination appeared safe for patients with renal cell carcinoma receiving immune checkpoint inhibitors, according to retrospective study results presented at International Kidney Cancer Symposium.

The FDA placed a clinical hold on a series of clinical trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.

The FDA approved the combination of pembrolizumab and lenvatinib for first-line treatment of adults with advanced renal cell carcinoma.